膵がん精密医療の市場規模、シェア、動向分析レポート：治療アプローチ別、診断技術別、地域別、セグメント動向：2025年～2030年

膵がん精密医療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の膵臓がん精密医療市場規模は、予測期間中にCAGR 19.2％を記録し、2030年までに18億8,000万米ドルに達すると予測されています。

膵臓がん精密医療産業は、生存率を高め副作用を最小化する標的療法や免疫療法の採用増加により成長を経験しています。リキッドバイオプシーや分子プロファイリングを含む先進的診断ツールは、早期発見と治療効果を改善しました。この精密医療へのシフトは、より効果的で個別化された治療戦略を促進しました。

技術の進歩、特に次世代シーケンサーとバイオインフォマティクスの統合は、新たな治療標的の発見を容易にし、より効果的な薬剤設計を可能にしました。製薬会社、学術機関、政府機関は投資を増やし、革新的な治療法の開発を支援しました。PanCAN助成金プログラムなどのイニシアチブは、膵がん研究への資金提供へのコミットメントを示し、市場成長を牽引しました。

膵臓がんの罹患率の上昇は、ライフスタイル要因や高齢化によって影響を受け、専門的な治療に対する高い需要を生み出しました。キャンサー・オーストラリアは、2024年に国内で新たに4,641人の膵がん患者が診断されたと推定しています。このような有病率の増加は、医療プロバイダーがより効果的な選択肢を求めるようになり、市場の成長を後押ししました。さらに、製薬企業と研究機関の戦略的提携や規制当局の支援が、市場の成長をさらに加速させました。

膵がん精密医療市場レポートハイライト

• 治療アプローチ別では、標的治療が市場を独占し、2024年には56.0%のシェアを占めました。
• 一方、化学療法と精度の高い併用療法は、予測期間中に最も速いCAGRで成長する見込みです。
• 診断技術別では、ゲノム検査が市場をリードし、2024年には40.8%を占めます。実用的な変異を同定するその役割は、個別化治療に不可欠であることが証明されました。
• ctDNAとCTC分析による早期発見のための低侵襲的方法である液体生検は、患者の転帰改善により、予測期間中最も速いCAGR 20.3％で成長すると予測されます。
• 標的療法や免疫療法の採用が進み、先進的な診断法と相まって、生存率を高め、効果的な精密医療戦略を調整することで市場の成長を促進しています。
• 北米は、高い罹患率と効果的な治療に対する需要に牽引され、42.9％の売上高シェアで世界の膵がん精密医療産業を支配しました。
• 膵臓がん精密医療産業で事業を展開する市場参入企業には、AstraZeneca、Pfizer Inc.、Novartis AG、Amgen Inc.、F. Hoffmann-La Roche Ltd、Bayer AG、Eli Lilly and Company、Merck & Co., Inc.、Teva Pharmaceutical Industries Ltd、PharmaCyte Biotech, Inc.、Genentech, Inc.、Guardant Health、Illumina, Inc.、Thermo Fisher Scientific Inc.、FOUNDATION MEDICINE, INCが含まれます。
• 2024年8月、Illumina Inc.はNovaSeq Xシリーズの顧客向けに新しいオンコロジーメニューを開始し、世界中の顧客のために、より低コストかつ大規模で包括的なゲノムプロファイリングを拡大しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 膵臓がん精密医療市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 膵臓がん精密医療市場：治療アプローチビジネス分析

• 治療アプローチ市場シェア、2024年と2030年
• 治療アプローチセグメントダッシュボード
• 市場規模と予測と動向分析、治療アプローチ別、2018～2030年
• 標的療法
• PARP阻害剤
• モノクローナル抗体
• 低分子阻害剤-EGFR阻害剤、KRAS阻害剤
• 免疫療法
• 免疫チェックポイント阻害剤-PD-1阻害剤、PD-L1阻害剤
• がんワクチン-GVAX、アルゲンパントゥセル-L
• 養子T細胞療法-CAR-T療法
• 化学療法の精密な組み合わせ
• その他

第5章 膵臓がん精密医療市場：診断技術ビジネス分析

• 診断技術市場シェア、2024年と2030年
• 診断技術セグメントダッシュボード
• 市場規模と予測と動向分析、診断技術別、2018～2030年
• ゲノム検査
• 分子診断
• 液体生検
• バイオマーカーベースのコンパニオン診断
• その他（免疫組織化学（IHC）、プロテオミクス、質量分析）

第6章 膵臓がん精密医療市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 国別、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • AstraZeneca
  • Pfizer Inc.
  • Novartis AG
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd
  • PharmaCyte BIoTech, Inc.
  • Genentech, Inc.
  • Guardant Health
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • FOUNDATION MEDICINE, INC.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global pancreatic cancer precision medicine market, by region, 2018 - 2030 (USD Million)
• Table 4 Global pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 5 Global pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 6 North America pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 7 North America pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 8 North America pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 9 U.S. pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 10 U.S. Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 11 Canada pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 12 Canada pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 13 Mexico pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 14 Mexico pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 15 Europe pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 17 Europe pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 18 UK pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 19 UK Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 20 Germany pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 21 Germany pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 22 France pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 23 France Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 24 Italy pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 25 Italy pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 26 Spain pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 27 Spain pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 28 Norway pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 29 Norway Pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 30 Denmark pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 31 Denmark pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 32 Sweden pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 33 Sweden pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 37 Japan pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 38 Japan pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 39 China pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 40 China pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 41 India pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 42 India pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 43 Australia pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 44 Australia pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 45 South Korea pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 46 South Korea pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 47 Thailand pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 48 Thailand pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 49 Latin America pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 50 Latin America pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 51 Latin America pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 52 Brazil pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 53 Brazil pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 54 Argentina pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 55 Argentina pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Pancreatic cancer precision medicine market, by country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 59 South Africa pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 60 South Africa pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 63 UAE pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 64 UAE pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)
• Table 65 Kuwait pancreatic cancer precision medicine market, by therapeutic approach, 2018 - 2030 (USD Million)
• Table 66 Kuwait pancreatic cancer precision medicine market, by diagnostic technology, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Pancreatic cancer precision medicine market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and diagnostic technology outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Pancreatic cancer precision medicine market dynamics
• Fig. 12 Pancreatic cancer precision medicine market: Porter's five forces analysis
• Fig. 13 Pancreatic cancer precision medicine market: PESTLE analysis
• Fig. 14 Pancreatic cancer precision medicine market: Therapeutic approach segment dashboard
• Fig. 15 Pancreatic cancer precision medicine market: Therapeutic approach market share analysis, 2024 & 2030
• Fig. 16 Targeted therapy market, 2018 - 2030 (USD Million)
• Fig. 17 PARP inhibitors market, 2018 - 2030 (USD Million)
• Fig. 18 Monoclonal antibodies market, 2018 - 2030 (USD Million)
• Fig. 19 Small molecule inhibitors - EGFR inhibitors, KRAS inhibitors market, 2018 - 2030 (USD Million)
• Fig. 20 Immunotherapy market, 2018 - 2030 (USD Million)
• Fig. 21 Immune checkpoint inhibitors - PD-1 inhibitors, PD-L1 inhibitors market, 2018 - 2030 (USD Million)
• Fig. 22 Cancer vaccines - GVAX, Algenpantucel-L market, 2018 - 2030 (USD Million)
• Fig. 23 Adoptive T-Cell therapies - CAR-T therapies market, 2018 - 2030 (USD Million)
• Fig. 24 Chemotherapy-precision combinations market, 2018 - 2030 (USD Million)
• Fig. 25 Other therapeutic approaches market, 2018 - 2030 (USD Million)
• Fig. 26 Pancreatic cancer precision medicine market: Diagnostic technology segment dashboard
• Fig. 27 Pancreatic cancer precision medicine market: Diagnostic technology market share analysis, 2024 & 2030
• Fig. 28 Genomic testing market, 2018 - 2030 (USD Million)
• Fig. 29 Molecular diagnostics market, 2018 - 2030 (USD Million)
• Fig. 30 Liquid biopsy market, 2018 - 2030 (USD Million)
• Fig. 31 Biomarker-based companion diagnostics market, 2018 - 2030 (USD Million)
• Fig. 32 Others (Immunohistochemistry (IHC), proteomics, mass spectrometry) market, 2018 - 2030 (USD Million)
• Fig. 33 Pancreatic cancer precision medicine market revenue, by region
• Fig. 34 Regional marketplace: Key takeaways
• Fig. 35 Regional marketplace: Key takeaways
• Fig. 36 North America pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. country dynamics
• Fig. 38 U.S. pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 39 Canada country dynamics
• Fig. 40 Canada pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 41 Mexico country dynamics
• Fig. 42 Mexico pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 43 Europe pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 44 UK country dynamics
• Fig. 45 UK pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 46 Germany country dynamics
• Fig. 47 Germany pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 48 France country dynamics
• Fig. 49 France pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 50 Italy country dynamics
• Fig. 51 Italy pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 52 Spain country dynamics
• Fig. 53 Spain pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 54 Norway country dynamics
• Fig. 55 Norway pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 56 Sweden country dynamics
• Fig. 57 Sweden pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 58 Denmark country dynamics
• Fig. 59 Denmark pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 60 Asia Pacific pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 61 Japan country dynamics
• Fig. 62 Japan pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 63 China country dynamics
• Fig. 64 China pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 65 India country dynamics
• Fig. 66 India pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 67 Australia country dynamics
• Fig. 68 Australia pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 69 South Korea country dynamics
• Fig. 70 South Korea pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 71 Thailand country dynamics
• Fig. 72 Thailand pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 73 Latin America pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 74 Brazil country dynamics
• Fig. 75 Brazil pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 76 Argentina country dynamics
• Fig. 77 Argentina pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 78 MEA pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 79 South Africa country dynamics
• Fig. 80 South Africa pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 81 Saudi Arabia country dynamics
• Fig. 82 Saudi Arabia pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 83 UAE country dynamics
• Fig. 84 UAE pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 85 Kuwait country dynamics
• Fig. 86 Kuwait pancreatic cancer precision medicine market, 2018 - 2030 (USD Million)
• Fig. 87 Company categorization
• Fig. 88 Company market position analysis
• Fig. 89 Strategic framework

Pancreatic Cancer Precision Medicine Market Growth & Trends:

The global pancreatic cancer precision medicine market size is anticipated to reach USD 1.88 billion by 2030, registering a CAGR of 19.2% during the forecast period, according to a new report by Grand View Research, Inc. The pancreatic cancer precision medicine industry experiences growth due to the increasing adoption of targeted therapies and immunotherapies, which enhanced survival rates and minimized side effects. Advanced diagnostic tools, including liquid biopsies and molecular profiling, improved early detection and treatment efficacy. This shift towards precision medicine facilitated more effective, individualized treatment strategies.

Technological progress, specifically the integration of next-generation sequencing and bioinformatics, facilitated the discovery of new therapeutic targets, enabling more effective drug design. Pharmaceutical companies, academic institutions, and government organizations increased their investments, supporting the development of innovative therapies. Initiatives such as the PanCAN grants program demonstrated a commitment to funding pancreatic cancer research, driving market growth.

The rising incidence of pancreatic cancer, influenced by lifestyle factors and an aging population, created a higher demand for specialized treatments. In 2024, Cancer Australia estimated 4,641 new pancreatic cancer cases were diagnosed in the country. This growing prevalence propelled market growth as healthcare providers sought more effective options. Furthermore, strategic collaborations between pharmaceutical companies and research institutions and regulatory support further accelerated market growth.

Pancreatic Cancer Precision Medicine Market Report Highlights:

• Based on therapeutic approach, targeted therapy dominated the market and accounted for a share of 56.0% in 2024, owing to by advancements in personalized treatment and genomic profiling.
• Chemotherapy-precision combinations, on the other hand, is expected to grow at the fastest CAGR of over the forecast period.
• Based on diagnostic technology, genomic testing led the market and accounted for 40.8% in 2024. Its role in identifying actionable mutations proved essential for personalized treatment.
• Liquid biopsies, a minimally invasive method for early detection via ctDNA and CTC analysis, are projected to grow at the fastest CAGR of 20.3% over the forecast period, driven by improved patient outcomes.
• The increasing adoption of targeted therapies and immunotherapies, coupled with advanced diagnostics, fuels market growth by enhancing survival rates and tailoring effective precision medicine strategies.
• North America dominated the global pancreatic cancer precision medicine industry with a 42.9% revenue share, driven by high incidence rates and demand for effective treatments.
• Market players operating in the pancreatic cancer precision medicine industry include AstraZeneca; Pfizer Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd; PharmaCyte Biotech, Inc.; Genentech, Inc.; Guardant Health; Illumina, Inc.; Thermo Fisher Scientific Inc.; FOUNDATION MEDICINE, INC.
• In August 2024, Illumina Inc. launched a new oncology menu for its NovaSeq X Series customers, expanding comprehensive genomic profiling at lower costs and greater scale for customers worldwide.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic Approach
  • 1.2.2. Diagnostic Technology
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pancreatic Cancer Precision Medicine Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Pancreatic Cancer Precision Medicine Market: Therapeutic Approach Business Analysis

• 4.1. Therapeutic Approach Market Share, 2024 & 2030
• 4.2. Therapeutic Approach Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Approach, 2018 to 2030 (USD Million)
• 4.4. Targeted Therapy
  • 4.4.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
• 4.5. PARP Inhibitors
  • 4.5.1. PARP Inhibitors Market, 2018 - 2030 (USD Million)
• 4.6. Monoclonal Antibodies
  • 4.6.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
• 4.7. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors
  • 4.7.1. Small Molecule Inhibitors - EGFR Inhibitors, KRAS Inhibitors Market, 2018 - 2030 (USD Million)
• 4.8. Immunotherapy
  • 4.8.1. Immunotherapy Market, 2018 - 2030 (USD Million)
• 4.9. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors
  • 4.9.1. Immune Checkpoint Inhibitors - PD-1 Inhibitors, PD-L1 Inhibitors Market, 2018 - 2030 (USD Million)
• 4.10. Cancer Vaccines - GVAX, Algenpantucel-L
  • 4.10.1. Cancer Vaccines - GVAX, Algenpantucel-L Market, 2018 - 2030 (USD Million)
• 4.11. Adoptive T-Cell Therapies - CAR-T Therapies
  • 4.11.1. Adoptive T-Cell Therapies - CAR-T Therapies Market, 2018 - 2030 (USD Million)
• 4.12. Chemotherapy-Precision Combinations
  • 4.12.1. Chemotherapy-Precision Combinations Market, 2018 - 2030 (USD Million)
• 4.13. Other Therapeutic Approaches
  • 4.13.1. Other Therapeutic Approaches Market, 2018 - 2030 (USD Million)

Chapter 5. Pancreatic Cancer Precision Medicine Market: Diagnostic Technology Business Analysis

• 5.1. Diagnostic Technology Market Share, 2024 & 2030
• 5.2. Diagnostic Technology Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Diagnostic Technology, 2018 to 2030 (USD Million)
• 5.4. Genomic Testing
  • 5.4.1. Genomic Testing Market, 2018 - 2030 (USD Million)
• 5.5. Molecular Diagnostics
  • 5.5.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
• 5.6. Liquid Biopsy
  • 5.6.1. Liquid Biopsy Market, 2018 - 2030 (USD Million)
• 5.7. Biomarker-based Companion Diagnostics
  • 5.7.1. Biomarker-based Companion Diagnostics Market, 2018 - 2030 (USD Million)
• 5.8. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry)
  • 5.8.1. Others (Immunohistochemistry (IHC), Proteomics, Mass Spectrometry) Market, 2018 - 2030 (USD Million)

Chapter 6. Pancreatic Cancer Precision Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Pancreatic Cancer Precision Medicine Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AstraZeneca
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Pfizer Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Novartis AG
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Amgen Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. F. Hoffmann-La Roche Ltd
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Bayer AG
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Eli Lilly and Company
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Merck & Co., Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Teva Pharmaceutical Industries Ltd
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. PharmaCyte Biotech, Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Genentech, Inc.
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. Guardant Health
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic Initiatives
  • 7.5.13. Illumina, Inc.
    • 7.5.13.1. Overview
    • 7.5.13.2. Financial Performance
    • 7.5.13.3. Product Benchmarking
    • 7.5.13.4. Strategic Initiatives
  • 7.5.14. Thermo Fisher Scientific Inc.
    • 7.5.14.1. Overview
    • 7.5.14.2. Financial Performance
    • 7.5.14.3. Product Benchmarking
    • 7.5.14.4. Strategic Initiatives
  • 7.5.15. FOUNDATION MEDICINE, INC.
    • 7.5.15.1. Overview
    • 7.5.15.2. Financial Performance
    • 7.5.15.3. Product Benchmarking
    • 7.5.15.4. Strategic Initiatives